Top International Companies To Buy Right Now

Southwest Airlines (LUV) recently completed its 41st consecutive year of profitability – a stunning number for any airline.

And following better-than-expected Q4 results in January, analysts revised their earnings estimates significantly higher for Southwest for both 2014 and 2015. This sent Southwest Airlines stock to a Zacks Rank #1 (Strong Buy). Estimates have continued to climb as the company approaches its Q1 earnings release on April 24.

Southwest Airlines is the nation’s largest carrier in terms of originating domestic passengers boarded. Including AirTran (which it acquired in 2011), it operates the largest fleet of Boeing aircraft in the world, serving 96 destinations in 41 states, the District of Columbia, Puerto Rico, and five near-international countries.

Hot Companies To Buy Right Now: Tandem Diabetes Care Inc (TNDM)

Tandem Diabetes Care, Inc., incorporated on July 1, 2008, is a medical device company with an approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The Company designed and commercialized its flagship product, the t:slim Insulin Delivery System, or t:slim, based on its technology platform and consumer-focused approach. Its technology platform features Micro-Delivery Technology, a miniaturized pumping mechanism, which draws insulin from a flexible bag within the pump�� cartridge rather than relying on a syringe and plunger mechanism. The Company also applies the science of human factors to its design and development process, which seeks to optimize its devices to the intended users, allowing users to successfully operate the devices in their intended environment.

The Company developed t:slim to offer the specific features that people with insulin-dependent diabetes seek in a next-generation insulin pump. The Company designed it to have the look and feel of a modern consumer electronic device, such as a smartphone. It is the insulin pump to feature a high resolution, color touchscreen. It is also the slimmest and smallest durable insulin pump on the market, and can easily and discreetly fit into a pocket, while still carrying a cartridge with 300 units of insulin.

The Company designed its flagship product, t:slim, to have the look and feel of a modern consumer electronic device, such as a smartphone. t:slim is the slimmest and smallest durable insulin pump on the market. With its narrow profile, which is similar to many smartphones, t:slim can easily and discreetly fit into a pocket. Its technology platform allows for the use of a vivid touchscreen and easy-to-navigate software architecture, which provide users simple access to the key functions of t:slim directly from the Home Screen. Insulin pump users can quickly learn how to efficiently navigate t:slim�� software, thereby enabling healthcare providers to spend! less time teaching a person how to use the pump and more time improving management of their diabetes. Its software also features numerous shortcuts, including a simple way to return to the Home Screen and view critical information for therapy management. Its technology is specifically designed to help prevent the unintentional delivery of insulin and reduce fear associated with using a pump.

Advisors' Opinion:

• [By Paul Ausick]

  Insulin pump maker Tandem Diabetes Care Inc. (NASDAQ: TNDM) sold 8 million shares on Thursday at an IPO price of $15. The stock began trading at around $19 before closing about flat to the opening bid and then shooting up more than 13% on Friday to close at $21.84.

Top International Companies To Buy Right Now: Spdr S&P Pharmaceuticals Etf (XPH)

SPDR S&P Pharmaceuticals Exchange Traded Fund (The Fund) seeks to replicate as closely as possible, before expenses, the performance of an index derived from the pharmaceuticals segment of a United States total market composite index. The Fund uses a passive management strategy designed to track the total return performance of the S&P Pharmaceuticals Select Industry Index (the Pharmaceuticals Index).

The Pharmaceuticals Index represents the pharmaceuticals sub-industry portion of the S&P TMI. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange (NYSE), American Stock Exchange (AMEX), National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Advisors' Opinion:

• [By Selena Maranjian]

  Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some pharmaceutical stocks to your portfolio, the SPDR S&P Pharmaceuticals ETF (NYSEMKT: XPH  ) could save you a lot of trouble. Instead of trying to figure out which companies will perform best, you can use this ETF to invest in lots of them simultaneously.
  
  The basics
  ETFs often sport lower expense ratios than their mutual fund cousins. The SPDR ETF's expense ratio -- its annual fee -- is a relatively low 0.35%.
  
  This ETF has trounced the world markets over the past three and five years. As with most investments, of course, we can't expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver.

Top International Companies To Buy Right Now: EDAP TMS S.A.(EDAP)

EDAP TMS S.A., through its subsidiaries, engages in the development, manufacture, and marketing of minimally invasive medical devices primarily for urological diseases. The company operates in two divisions, High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS). The HIFU division involves in the development, manufacture, and marketing of medical devices based on HIFU technology for the minimally invasive destruction of various types of localized tumors. This division offers Ablatherm, a HIFU-based ultrasound guided device for the treatment of organ-confined prostate cancer. Its HIFU technology allows the surgeon to destroy a defined area of diseased tissue without damaging surrounding tissue and organs. This division also engages in the leasing of equipment, as well as the sale of disposables, spare parts, and maintenance services. This division markets and sells its products through its direct marketing and sales organization, as well as through third-party distributors and agents. The UDS division engages in the development, manufacture, marketing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, primarily urinary stones and other clinical indications. This division provides lithotripters for the treatment of urinary tract stones by means of ESWL technology. This division manufactures three models of lithotripters: the Sonolith Praktis, the Sonolith i-move, and the Sonolith i-sys. This division also involves in the leasing of lithotripters, as well as the sale of disposables, spare parts, and maintenance services. This division markets and sells its products through its direct sales and service platform, as well as through agents and third-party distributors. The company?s customers include public and private hospitals, urology clinics, and research institutions worldwide. EDAP TMS S.A. was founded in 1979 and is based in Vaulx-en-Velin, France.

Advisors' Opinion:

• [By Bryan Murphy]

  Last week, yours truly posed the unpopular (though largely ignored) premise that EDAP TMS S.A. (NASDAQ:EDAP) was poised to tumble. It wasn't anything personal, nor was it a judgment call on the merits of the company. It was simply a trading-based call, observing how the rally EDAP was enjoying at the time appeared to be running out of gas, and there was no floor to halt any pullback.

• [By John Udovich]

  Laparoscopic surgery or minimally invasive surgery (MIS) is a type of surgical technique where�operations in the abdomen are performed through small incisions while small cap stocks ArthroCare Corporation (NASDAQ: ARTC), EDAP TMS S.A. (NASDAQ: EDAP), SafeStitch Medical Inc (OTCBB: SFES) and Arch Therapeutics Inc (OTCBB: ARTH) are all in some way focused on aiding minimally invasive procedures. According to a 2012 report produced by MedMarket Diligence, LLC, approximately 114 million surgical and procedure-based wounds occur annually worldwide,�including�36 million in the US, and perhaps�up to a quarter of these procedures can be described as laparoscopic in nature.�Moreover,�use of the technique is bound to increase�as�it reduces�pain and hemorrhaging plus leads to a�shorter recovery time.

• [By Bryan Murphy]

  This isn't going to be a well-received idea, given how bullish the stock appears to be at this time, but EDAP TMS S.A. (NASDAQ:EDAP) is a sell. Up 82% since the end of May, EDAP is ripe for a pullback, and may have reached the bearish pivot point as of today.

Top International Companies To Buy Right Now: SIGA Technologies Inc.(SIGA)

SIGA Technologies, Inc., a pharmaceutical company, engages in the development and commercialization of pharmaceutical solutions for smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. Its lead product is ST-246, an orally administered antiviral drug that targets orthopoxviruses. The company also has two drug series in the pre-clinical development stage against four serotypes of virus for dengue disease. In addition, it is developing anti-arenavirus drug for hemorrhagic fever arenaviruses and other hemorrhagic fever viruses, including Rift Valley Fever, Lymphocytic choriomeningitis virus, and Ebola; and a broad spectrum antiviral candidate against viruses in the Poxviridae, Filoviridae, Bunyaviridae, Arenaviridae, Flaviviridae, Togaviridae, Retroviridae, and Picornaviridae families. The company was founded in 1995 and is headquartered in New York, New York.

Advisors' Opinion:

• [By Monica Gerson]

  SIGA Technologies (NASDAQ: SIGA) is expected to post its Q4 earnings at $0.62 per share on revenue of $47.00 million.

  Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets